Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Haptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy.

Anticancer chemotherapy is an underappreciated contributor to cancer cachexia, an often-irreversible body-wasting condition that causes 20%-30% of cancer-related deaths. An obstacle to predicting, monitoring and understanding the mechanisms underlying chemotherapy cachexia is that each cancer (and subtype) is assigned different...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHaptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy.

Early Detection of Age-Related Decline of Muscle Cell Mass by Intracellular Water Assessment Compared With MRI or DXA.

Ageing is commonly associated with a decrease in muscle strength, which is largely linked to decreases in skeletal muscle mass (SMM). The rate of the age-related decline in muscle strength is different from the rate of the age-related decline in...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEarly Detection of Age-Related Decline of Muscle Cell Mass by Intracellular Water Assessment Compared With MRI or DXA.

Novel Aptamers Targeting Sclerostin Loop3 Improve Skeletal and Muscle Properties Without Adverse Cardiovascular Effects in Orchiectomized Mice.

The Wnt/ฮฒ-catenin pathway and its bone-specific inhibitor, sclerostin, play important roles in skeletal development and homeostasis. The humanized sclerostin antibody, romosozumab, can significantly increase bone mineral density (BMD) of patients with osteoporosis, but it may also increase cardiovascular adverse events,...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNovel Aptamers Targeting Sclerostin Loop3 Improve Skeletal and Muscle Properties Without Adverse Cardiovascular Effects in Orchiectomized Mice.

Prediction of 10-Year Fragility Fractures Using Muscle Health Indicators in Postmenopausal Women: The OsteoLaus Cohort.

Muscle strength, mass and function have been associated with falls, fractures and mortality, but the results vary between previous studies. We aimed to investigate the predictive ability of muscle strength and mass with 10-year incident fragility fractures. This study included...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrediction of 10-Year Fragility Fractures Using Muscle Health Indicators in Postmenopausal Women: The OsteoLaus Cohort.

Comment on "Diagnosis of Sarcopenia by Evaluating Skeletal Muscle Mass by Adjusted Bioimpedance Analysis Validated With Dual-Energy X-Ray Absorptiometry" by Cheng etย al.-The Authors Reply.

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on "Diagnosis of Sarcopenia by Evaluating Skeletal Muscle Mass by Adjusted Bioimpedance Analysis Validated With Dual-Energy X-Ray Absorptiometry" by Cheng etย al.-The Authors Reply.

ZBED6 Knockout Prevents Ageing- and Dexamethasone-Induced Muscle Atrophy via Dkk3 in Pig and Mice.

Effective treatments for skeletal muscle atrophy, a debilitating condition linked to ageing and glucocorticoid therapy, remain lacking. Zinc finger BED-type containing 6 (ZBED6), a transcriptional repressor, enhances muscle growth and protects against sepsis-induced atrophy, but its role in ageing- and...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreZBED6 Knockout Prevents Ageing- and Dexamethasone-Induced Muscle Atrophy via Dkk3 in Pig and Mice.

Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population.

Sarcopenia is defined as the loss of muscle mass, strength, and/or performance. It is strongly associated with all-cause mortality. Fibroblast growth factor 23 (FGF23) is markedly elevated in patients with chronic kidney disease, especially those receiving maintenance dialysis. FGF23 has...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population.

MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction-Regulating Proteins in a Rat Model of HFpEF.

Heart failure with preserved ejection fraction (HFpEF) is associated with exercise intolerance, accompanied by alterations in the peripheral skeletal muscle (SKM). We have recently shown that titin, a giant sarcomere protein, is hyperphosphorylated in HFpEF. MuRF1 is a muscle-specific ubiquitin...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction-Regulating Proteins in a Rat Model of HFpEF.

Comment on 'Acute Sarcopenia: Systematic Review and Meta-Analysis on Its Incidence and Muscle Parameter Shifts During Hospitalisation' by Aldrich etย al.: The Authors' Reply.

๐Ÿ—“๏ธ 2025-01-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on 'Acute Sarcopenia: Systematic Review and Meta-Analysis on Its Incidence and Muscle Parameter Shifts During Hospitalisation' by Aldrich etย al.: The Authors' Reply.

Androgen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.

Androgen deprivation therapy (ADT) increases the risk of adverse cardiovascular events in patients with prostate cancer. ADT can induce body composition change; however, the association between body composition change and cardiovascular outcomes remains unclear. This study aimed to determine the...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAndrogen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.

Myogenic nano-adjuvant for orthopedic-related sarcopenia via mitochondrial homeostasis modulation in macrophage-myosatellite metabolic crosstalk.

The decline in skeletal muscle mass and muscle strength linked to aging, also known as sarcopenia, is strongly associated with disability, traumatic injury, and metabolic disease in patients. Meanwhile, sarcopenia increases the risk of adverse orthopedic perioperative complications including implant...

๐Ÿ—“๏ธ 2025-05-28
๐Ÿ“ฐ Publication: Journal Of Nanobiotechnology
Read MoreMyogenic nano-adjuvant for orthopedic-related sarcopenia via mitochondrial homeostasis modulation in macrophage-myosatellite metabolic crosstalk.

Normative data for age-specific skeletal muscle area based on computed tomography in Korean population.

Sarcopenia, a progressive loss of muscle mass and function, increases health risks in older adults, especially in rapidly ageing populations like Korea. Computed tomography (CT) imaging at the third lumbar vertebra (L3) level is a gold standard for assessing skeletal...

๐Ÿ—“๏ธ 2025-05-03
๐Ÿ“ฐ Publication: Age And Ageing
Read MoreNormative data for age-specific skeletal muscle area based on computed tomography in Korean population.

Iron Metabolism and Muscle Aging: Where Ferritinophagy Meets Mitochondrial Quality Control.

In older adults with reduced physical performance, an increase in the labile iron pool within skeletal muscle is observed. This accumulation is associated with an altered expression of mitochondrial quality control (MQC) markers and increased mitochondrial DNA damage, supporting the...

๐Ÿ—“๏ธ 2025-05-03
Read MoreIron Metabolism and Muscle Aging: Where Ferritinophagy Meets Mitochondrial Quality Control.

Potential framework of the Global Leadership Initiative in Sarcopenia (GLIS) criteria based on muscle mass and/or strength for predicting survival in cancer patients: A nationwide multicenter cohort study.

The Global Leadership Initiative on Sarcopenia (GLIS) was proposed recently by creating a widely recognized conceptual definition of sarcopenia, however, the diagnostic framework of GLIS in cancer patients remains unclear. This study aims to evaluate the potential framework of GLIS...

๐Ÿ—“๏ธ 2025-04-24
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MorePotential framework of the Global Leadership Initiative in Sarcopenia (GLIS) criteria based on muscle mass and/or strength for predicting survival in cancer patients: A nationwide multicenter cohort study.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!